🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the fight against drug-resistant strains of the bacteria, according to health experts.

An International Public Health Issue

Gonorrhoea infections are increasing worldwide, with estimates suggesting over 82 million infections per year. Especially elevated rates are reported in Africa and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an important and timely development in the reality of rising global incidence, escalating drug resistance and the extremely scarce available drugs at this time.”

Medical experts are deeply concerned about the increase in drug-resistant strains. The WHO has classified it as a "high-priority threat". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Gain Authorization

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in recent days for combating gonorrhoea. This disease can lead to serious health problems, including infertility. Experts believe that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, developed by the pharmaceutical company GSK, was also approved in the same week. This drug, which is also used to treat urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This milestone represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Testing Outcomes and Worldwide Availability

Based on findings detailed in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the current standard treatment, which uses a dual-drug approach. The research involved hundreds of patients from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to make available and distribute the drug in a wide range of regions with limited resources.

Doctors treating patients have shared optimism. The availability of a one-pill regimen like this is seen as a "critical tool" for public health efforts. This is deemed essential to alleviate the strain of the infection for people and to stop the proliferation of untreatable gonorrhoea globally.